THYROID CANCERS

Maria E. Cabanillas, MD, discusses the pooled results of 2 larotrectinib trials for patients with advanced or metastatic TRK fusion-positive thyroid cancer.

The combination of ipilimumab with nivolumab induced an objective response rate of 12% as treatment of patients with thyroid cancer.

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.

Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.

In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.

Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.

A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.

Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.

Patients with medullary thyroid cancer harboring abberations in RET who were treated with pralsetinib across therapy lines exhibited potent and durable clinical activity, according to results presented at the ESMO Virtual Congress 2020 from the phase 1/2 ARROW clinical trial.

Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.

The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.

The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.

In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the evolution she has observed in thyroid cancer in terms of the use of targeted therapies and other important milestones for this patient population.

A real-world study assessed the performance of this system in patients with differentiated thyroid cancer and discovered that the system is reliable for predicting short-term outcomes.

Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they received prior vandetanib or cabozantinib in the phase 1/2 LIBRETTO-001 study.